Business Context and Reporting Period
Company: NERVGEN PHARMA CORP.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: August 13, 2026
Reporting Period: This filing incorporates by reference interim financial statements and management discussion for the three and six months ended June 30, 2026.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. The following metrics are referenced as being included in the attached exhibits but are not detailed in this text:
- Revenue, Profit, and Cash Flow: Refer to Exhibit 99.1 (Condensed Consolidated Interim Financial Statements).
- Margins, Debt, and Liquidity: Refer to Exhibit 99.2 (Management's Discussion and Analysis).
- Specific Values: The filing text does not provide a clear value for any financial metric.
Material Changes
The text does not explicitly state material changes versus the prior comparable period. Comparative data for the three and six months ended June 30, 2025, is referenced in Exhibit 99.1 and 99.2, but the specific variances are not described in the cover document.
Guidance, Outlook, and Risks
Management Commentary: Refer to Exhibit 99.2 for the Management's Discussion and Analysis of Financial Condition and Results of Operations.
Recent Developments: Exhibit 99.3 contains a Press Release dated August 13, 2026, which may contain updates on operations or strategy.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 for actual revenue, net loss, and cash burn rates for the six months ended June 30, 2026.
- Examine Exhibit 99.2 for management's explanation of operational progress and liquidity position.
- Read Exhibit 99.3 (Press Release) for any new clinical trial updates or strategic announcements made on August 13, 2026.
- Verify the incorporation by reference into Registration Statements Form F-10 and Form S-8 as noted in the filing.